Mouse “avatars” in the treatment of progressive cancers

We’re not sure what to make of this one at all, but apparently some people are now willing to pay to have pieces of their tumor transplanted into laboratory mice to test whether specific drugs will work on their tumor in those mice. … READ MORE …

Access to, cost of, and value of high-price prostate (and other) cancer drugs

As all our regular readers will be well aware, it is not enough, in the UK, for a new cancer drug to be approved for use by the European Union and its European Medicines Agency. … READ MORE …

Evolution of the mCRPC treatment landscape

A new article by Jeffress in the cancer business publication OBR Green discusses the changing patterns of use of  the various approved drugs in the treatment of metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …

More on the costs of new cancer treatments

As some of our regular readers will be aware, a new form of cancer therapy known as “chimeric antigen receptor T-cell” therapy (often known as CART or CAR-T) is currently in advanced stages of development. … READ MORE …

The increasing high costs of drugs for cancer therapy

The news junkies among our readers probably already know this, but …. READ MORE …

The costs of new treatments for cancer: the economics of reality

As regular readers will be aware, The “New” Prostate Cancer InfoLink regularly notes that the continuing rise in the prices of new drugs for the treatment of prostate cancer (and many other conditions too) is unsustainable. And what we need to do about it is hard to work out. … READ MORE …

Why are the prices of new drugs today so high?

There is a very recent and interesting article on a Scientific American blog site called “The Curious Waveform”. It discusses the apparent disconnect between what it costs to manufacture a new drug today and the price we may be asked to pay for it. … READ MORE …

SHIVA trial studying response to molecular targeting strategy for drug therapy

At the upcoming meeting of the European Cancer Congress (ECC2013), starting on Friday, September 27 in Amsterdam, The Netherlands, Dr. Christophe Le Tourneau, Head of the Phase I Program at the Institut Curie, Paris, France, will give attendees an initial report on progress of the so-called SHIVA trial. … READ MORE …

Patient-reported outcomes and prostate cancer drug development

There is an excellent opinion piece in this this week’s New England Journal of Medicine that addresses the need for greater focus on patient-reported outcomes in the development of drugs for the treatment of cancer. … READ MORE …

Making drug approval data more “patient centric”

Many of our readers may be interested in an opinion-piece by Dr. Ethan Basch in this week’s issue of the New England Journal of Medicine. … READ MORE …

AUA also issues new guidance on treatment of patients with CRPC

Earlier today, the American Urological Association issued new guidance to its members on the management of patients with non-metastatic and metastatic castration-resistant prostate cancer (CRPC). … READ MORE …

The costs of new drugs to treat cancer (and other disorders)

In what is being described as “an extraordinary step” in some media reports, a group of more than 100 leukemia specialists has just published an article in the journal Blood asking for a real dialog with the biopharmaceutical industry about the constantly increasing costs associated with new (and older) drugs for the treatment of this form of cancer. … READ MORE …

Keeping progress in perspective — a message to Prof. Alan Ashworth

With the publication of data about enzalutamide in the New England Journal of Medicine last week, Professor Alan Ashworth, the head of the Institute for Cancer Research (ICR) in the UK, proclaimed “a golden age in prostate cancer drug discovery.” … READ MORE …

Why would anyone develop new drugs if international patent law can just be ignored?

There are two ways to look at a ruling issued yesterday by the Indian controller general of patents, designs and trademarks: it can either be seen as a major victory for patients who had no prior hope of treatment with a highly effective anticancer agent because of its cost … or it can be seen as an international setback to the entire concept of patent and intellectual property law. … READ MORE …

Taregted therapy and companion diagnostic: the AEZS-108 story

Here’s a clear signal that prostate cancer is entering the world of targeted therapeutics associated with specific companion diagnostics: the Canadian company Aeterna Zentaris has announced a partnership to develop a companion diagnostic to identify patients likely to respond to their targeted therapy AEZS-108. … READ MORE …